Dear s. martin, you are correct in stating <<To my knowledge you (an individual) can't even
short this stock unless you do it through a Canadian Brokerage.>> However, an
individual acting on behalf of market maker could be trying to cover short positions taken
when the stock was much higher. One way he could do that is to encourage (hype) people into
selling so that he could buy the required quantity of stock.
When you stated <<I am not short this (ADVR) stock.>> you proved to me that you are very
astute and nobodies fool. Who in their right mind would want to sell their stock [or short
if they could] with very good news pending about Reticulose and company related business.
Since I believe you to be astute, I'm suspicious that you could be long the ADVR stock.
If you really mean that <<they have no information to offer>>, it is an indication that you
are not reading all posts, just the ones that agree with you. So here are some repeats.
With your remarks concerning ABC 20/20, you seem to me to be indicating that ADVR is a scam.
I stated in one of my posts that after some 10-years and an SEC inquiry, no government official
has accused ADVR of being a scam, IF ADVR WERE A SCAM HOW DID THEY MANAGE TO
RECEIVE A GOVERNMENT CONTRACT FROM NIC/NIH?
My main motivation to post the first sentence from Dr. Hirschman's JIM abstract
along with his statements from Infectious Disease News was to inform readers of this
thread who do not have the capability of acquiring such information as a JIM
abstract or a doctors only medical trade magazine - even if they are willing to pay
for them. Since you continue to post negative statements [nonsense-to-fabrications]
I am re-posting the following because I don't believe that you have read them carefully.
The following is the first sentence of Dr. Hirschman's Biomedcine '96 abstract.
"Peptide nucleic acids (PNAs) are newly appreciated molecules consisting of both amino acids
and nucleosides that already have been shown to have interesting properties; for
example they are very stable and have ANTISENSE activity."
The following are statements Dr. Hirschman made in an interview for the Infectious Disease News
letter of 20 September 1996.
"Reticulose is a powerful stimulant of many CHEMOKINES. I gather, from its uses, that it
acts through the cell-mediated arm of the immune system and it may put the immune system in a
repair mode. Perhaps, most importantly, Reticulose was found to stimulate a distinct cassette
of CHEMOKINES, including INTERLEUKIN-1, INTERLEUKIN-6,
G-INTERFERON and TUMOR necrosis factor. Indeed, this suggests that Reticulose could
function as a broad antiviral drug operating via the immune system and may be useful in the
therapy of other conditions that require immune surveillance, such as neoplasias. Furthermore,
reticulose may also prove useful in repairing those conditions where the immune system has gone
awry by attacking self-proteins, such as is seen in diseases of autoimmunity. This opens
up a whole class of pharmacology. It is a new world of pharmacology. I can assure you that in
the next few years, peptide nucleic acids will be used to treat a
number of viruses."
The Infectious Disease News letter went on to state "If Reticulose does in fact stimulate a
repair of the immune system, it may provide both cell-mediated and humoral immunity."
I sincerely hope you realize that it is not the purchasing or shorting of stock nor the making
of money that is important, what is important is the availability of Reticulose,
all over the world, to alleviate the suffering occurring from deadly viral infections.
Kingfisher
. |
